

Review

Mortalin: a potential candidate for biotechnology and biomedicine

R. Wadhwa^{1,2}, K. Taira² and S.C. Kaul³

¹Chugai Research Institute for Medical Sciences, Nagai, Ibaraki, ²Gene Function Research Laboratory and ³Research Center for Glycoscience, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraki, Japan

Summary. Mortalin is a novel member of the hsp70 family of proteins that exhibits a different staining pattern in normal and immortal cells. It was also cloned as glucose regulated protein, GRP75 and peptide-binding protein, PBP74. It has been assigned multiple functions ranging from stress response, intracellular trafficking, antigen processing, control of cell proliferation, differentiation and tumorigenesis. The present article compiles and reviews information on multiple sites and functions of mortalin. In view of its upregulation in many tumors and transcriptional inactivation function of p53, its potential use in biotechnology and biomedicine is discussed.

Key words: Mortalin, mthsp70 chaperone, p53, MKT-077, Tumor therapy

Mouse and human mortalins

Mortalin was first cloned as a novel member of the hsp70 family of proteins present in the cytoplasmic fractions of normal fibroblasts from CD1-ICR mouse (Wadhwa et al., 1993a). An antibody raised against the full protein isolated from normal fibroblasts when used for cyto-immunochemistry revealed a cytoplasmic staining of the protein in normal cells; immortal cells showed the immunofluorescence in the perinuclear region (Wadhwa et al., 1993b). Immunocloning of cDNA from immortal cells (mot-2) and their sequence comparisons with the cDNA isolated from normal mouse cells (mot-1) revealed a difference of two amino acids in the carboxy-terminus (Wadhwa et al., 1993c). Genetic identities of mot-1 and mot-2 were obtained from mouse family studies that showed segregation of two loci in two mouse generations (Kaul et al., 2000a) illustrating that mot-1 and mot-2 are allelic in mouse and were assigned to chromosome 18 (Kaul et al., 1995;

Ohashi et al., 1995). Human normal and transformed cells also have differential staining of mortalin. Whereas normal cells have pancytoplasmic staining, more than 60 transformed cell lines analyzed to-date showed nonpancytoplasmic staining patterns (Fig. 1A) (Wadhwa et al., 1995; and unpublished observations). Biochemical studies have assigned the protein to subcellular localizations including mitochondria, endoplasmic reticulum, cytoplasmic vesicles and cytosol (Domanico et al., 1993; Dahlseid et al., 1994; Webster et al., 1994; Singh et al., 1997; Soltys and Gupta, 1999; Ran et al., 2000) of which mitochondria appeared to be a primary niche. Hence the protein is also called mthsp70 (Dahlseid et al., 1994; Webster et al., 1994; Bhattacharyya et al., 1995). In contrast to the mouse situation cloning of human mortalin cDNA from various human transformed cells showed identical sequences and was assigned to chromosome 5q31.1 (Kaul et al., 1995). Apparently, there are at least two mechanisms operating for differential distributions of the mortalin protein. One is by distinct cDNAs, mot-1 and mot-2 found in mouse, and the other by yet undefined protein modifications or cellular factors found in mouse and human cells.

Functional aspects of mortalin

Mortalin is expressed in all cell types and tissues so far examined (Wadhwa et al., 1995; Kaul et al., 1997) and is expected to perform some essential functions. Some of these predicted from its mitochondrial localization and studies on its yeast homologue ssc1 include mitochondrial import and biogenesis (Krimmer et al., 2000; Geissler et al., 2001). Mortalin expression was induced by low levels of ionizing radiation (Sadekova et al., 1997), glucose deprivation (Merrick et al., 1997), calcium ionophore (Resendez et al., 1985), ozone (Wu et al., 1999), hyperthyroidism (Craig et al., 1998; Schneider and Hood, 2000), muscle activity, and mitochondrial activity and biogenesis (Ornatsky et al., 1995; Ibi et al., 1996; Takahashi et al., 1998). Many of the human transformed and tumor-derived cells were seen to have a high level of mortalin expression (Takahashi et al., 1994; Bini et al., 1997; Takano et al.,

1997; Kaul et al., 1998; and unpublished observations). Introduction of mot-1 cDNA to NIH 3T3 cells induced cellular senescence like phenotype (Wadhwa et al., 1993c) whereas an overexpression of mot-2 cDNAs in NIH 3T3 cells resulted in their malignant transformation (Kaul et al., 1998). Similar to the mouse mot-2 cDNA, human mortalin cDNA induced malignant transformation of NIH 3T3 cells and was thus called hmot-2 (Kaul et al., 1998). Human lung fibroblasts when stably transfected with hmot-2 cDNA underwent extended population doublings *in vitro* (Kaul et al., 2000b). It was also shown that differentiation of HL-60 promyelocytic leukemia cells was accompanied by a decreased level of hmot-2/mthsp70 expression (Xu et al., 1999). An overexpression of hmot-2/mthsp70 imparted growth advantage and attenuated their differentiation (Xu et al., 1999). Other functions assigned to hmot-2/PBP74/mthsp70/GRP75 include antigen processing, *in vivo* nephrotoxicity and radioresistance (Domanico et al., 1993; Dahlseid et al., 1994; Merrick et al., 1997; Sadekova et al., 1997). hmot-2/mthsp70-p53 complexes were also detected in the mitochondria during p53-induced apoptosis (Marchenko et al., 2000) implicating its role in transcriptional-independent apoptotic signaling. Taken together, mortalin seems to play multiple functions relevant to the control of cellular proliferation and tumorigenesis.

Mechanisms of mortalin function

Studies on yeast homologue of mortalin have shown

that it acts as a mitochondrial import motor in unidirectional ATP-driven import of proteins from cytoplasm into mitochondria. This function is dependent on its anchoring to the inner mitochondrial membrane and interactions with an inner mitochondrial translocase TIM44, (Krimmer et al., 2000; Geissler et al., 2001) and is essential for survival. Malignant transformation of NIH 3T3, life span extension of MRC-5 and attenuation of differentiation of HL-60 cells by overexpression of mot-2 was explained, at least in part, by its p53 inactivation function. Mot-2 and p53 were shown to interact in the cytoplasm resulting in nuclear exclusion and transcriptional inactivation of the latter (Merrick et al., 1996; Wadhwa et al., 1998, 1999). Notably, mot-2 and p53 colocalized in human transformed, but not in normal, cells (Fig. 1B). Nuclear exclusion of wild type p53 was proposed as a possible mechanism of its inactivation for some tumors (Moll et al., 1992, 1996; Takahashi and Suzuki, 1994; Takahashi et al., 1994; Moll and Schramm, 1998). An overexpression of mot-2 in NIH 3T3 cells caused an abrogation of their serum-induced nuclear translocation of p53 (Fig. 1C). Studies using deletion mutants of mot-2 and p53 demonstrated that an amino-terminus region of mot-2 binds to the carboxy-terminus region of p53 (Kaul et al., 2001; Wadhwa et al., 2002) which was earlier defined as its cytoplasmic sequestration domain (Moll et al., 1996). These studies have suggested that mot-2 may sequester p53 in the cytoplasm by directly binding to its carboxy-terminus. Significantly, abrogation of mot-p53 interactions by MKT-077 (a water-soluble delocalized




Fig. 1. A. Immunostaining of mortalin in normal (MRC-5, lung fibroblast) and transformed human (HT1080, fibrosarcoma) cells. B. Double immunostaining of mortalin (red) and p53 (green) in normal (TIG-3, skin fibroblast) and transformed (A172, glioblastoma) human cells (experimental and technical details described in Wadhwa et al., 1998). Colocalization of mortalin and p53 is visible as a yellow staining in A172 cells. C. Abrogation of nuclear translocation of p53 by mot-2. GFP-tagged mot-2 microinjected cells (visible as green fluorescence) were stained with p53 (red) after serum starvation. The mot-2 injected cells were devoid of nuclear staining for p53. Uninjected cells showed the translocation of p53 (red) to the nucleus. (experimental and technical details described in Wadhwa et al., 1998).




Fig. 2. Nuclear translocation of p53 in MKT-077-treated human breast carcinoma (MCF-7) cells. Cells were treated with MKT-077 and double-stained for mortalin (red) and p53 (green) (experimental and technical details described in Wadhwa et al., 2000).




Fig. 3. p53-dependent reporter assay in MCF7 cells treated with MKT-077 and its analogues (experimental and technical details described in Wadhwa et al., 2000).

lipophilic cationic dye) that binds to mot-2 restored nuclear translocation (Fig. 2) and activation of p53 function (Fig. 3) followed by growth arrest of tumor cells (Wadhwa et al., 2000). These studies have shown

that inactivation of p53 by mot-2 may be functionally significant to tumorigenesis, at least, for the tumors which retain wild type p53. Therefore, targeting of mortalin expression by antisense, antibody or ribozyme technology or abrogation of its interactions with p53 can serve as a novel approach for cancer therapeutics. Besides, inactivation of p53 by overexpression of mot-2 can be employed in *in vitro* immortalization of human cells for bioindustry and biomedicine.

Other functions of mortalin, including chaperonization and mitochondrial biogenesis, may also be significantly important for control of division potential. It was shown that it binds to FGF-1 and aids in its intracellular trafficking (Mizukoshi et al., 1999) which was mediated by its cell cycle-specific phosphorylation (Mizukoshi et al., 2001). ATP-sensitive association of mortalin with the IL-1 receptor type was also detected and predicted to have a role in receptor internalization (Sacht et al., 1999). Its binding to glucose-regulated ER chaperone, GRP94 (Takano et al., 2001), may be involved in stress resistance and survival of cells. Further studies should elucidate the significance of each of these functions in control of cell proliferation and thus tumor growth and development.

Induction of senescence in transformed cells by introduction of a single chromosome (Nakabayashi et al., 1999), chromosome-fragments and genes (Bertram et al., 1999) or chemicals (Michishita et al., 1999; Wadhwa et al., 2000) was accompanied by reversion of subcellular distribution of mortalin from non-pancytoplasmic to the pancytoplasmic type. The

mechanism of such differential localizations, role of cytoskeleton elements, downstream signal transduction and its role in regulation of proliferation warrant further studies.

Prospective

Mortalin (mot-2/mthsp70) is an essential protein belonging to the hsp70 family of chaperones. It sojourns multiple subcellular sites while residing predominantly in mitochondria, and performs multiple functions including mitochondrial import, intracellular trafficking, receptor internalization and inactivation of tumor suppressor protein p53. A differential staining pattern of mortalin may predict its different functions in normal and transformed cells and can be used for identification of cellular divisional phenotype and thus for chemical screening for tumor therapeutics. Some of its functions, such as inactivation of p53, can be employed as an advantage for immortalization of human cells *in vitro* or can be targeted for tumor therapy. Targeting of other functions such as chaperonization, mitochondrial biogenesis and intracellular trafficking may have further potentials for biotechnology and biomedicine.

References

- Bertram M.J., Berube N.G., Swanson X.H. and Pereira-Smith O.M. (1999). Assembly of a BAC contig of the complementation group B cell senescence gene candidate region at 4q33-q34.1 and identification of expressed sequences. *Genomics* 56, 353-354.
- Bhattacharyya T., Karnezis A.N., Murphy S.P., Hoang T., Freeman B.C., Phillips B. and Morimoto R.I. (1995). Cloning and subcellular localization of human mitochondrial hsp70. *J. Biol. Chem.* 270, 1705-1710.
- Bini L., Magi B., Marzocchi B., Arcuri F., Tripodi S., Cintorino M., Sanchez J.C., Frutiger S., Hughes G., Pallini V., Hochstrasser D.F. and Tosi P. (1997). Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. *Electrophoresis* 18, 2832-2841.
- Craig E.E., Chesley A. and Hood D.A. (1998). Thyroid hormone modifies mitochondrial phenotype by increasing protein import without altering degradation. *Am. J. Physiol.* 275, C1508-1515.
- Dahlseid J.N., Lill R., Green J.M., Xu X., Qiu Y. and Pierce S.K. (1994). PBP74, a new member of the mammalian 70-kDa heat shock protein family, is a mitochondrial protein. *Mol. Biol. Cell* 5, 1265-1275.
- Domanico S.Z., DeNagel D.C., Dahlseid J.N., Green J.M. and Pierce S.K. (1993). Cloning of the gene encoding peptide-binding protein 74 shows that it is a new member of the heat shock protein 70 family. *Mol. Cell. Biol.* 13, 3598-3610.
- Geissler A., Rassow J., Pfanner N. and Voos W. (2001). Mitochondrial import driving forces: enhanced trapping by matrix hsp70 stimulates translocation and reduces the membrane potential dependence of loosely folded preproteins. *Mol. Cell. Biol.* 21, 7097-7104.
- Ibi T., Sahashi K., Ling J., Marui K. and Mitsuma T. (1996). Immunostaining of mitochondrial heat shock proteins (mtHSPs) in skeletal muscle fibers of mitochondrial cytopathy. *Rinsho Shinkeigaku Clinical Neurol.* 36, 61-64.
- Kaul S.C., Wadhwa R., Matsuda Y., Hensler P.J., Pereira-Smith O.M., Komatsu Y. and Mitsui Y. (1995). Mouse and human chromosomal assignments of mortalin, a novel member of the murine hsp70 family of proteins. *FEBS Lett.* 361, 269-272.
- Kaul S.C., Matsui M., Takano S., Sugihara T., Mitsui Y. and Wadhwa R. (1997). Expression analysis of mortalin, a unique member of the Hsp70 family of proteins, in rat tissues. *Exp. Cell Res.* 232, 56-63.
- Kaul S.C., Duncan E.L., Englezou A., Takano S., Reddel R.R., Mitsui Y. and Wadhwa R. (1998). Malignant transformation of NIH 3T3 cells by overexpression of mot-2 protein. *Oncogene* 17, 907-911.
- Kaul S.C., Duncan E.L., Sugihara T., Reddel R.R., Mitsui Y. and Wadhwa R. (2000a). Structurally and functionally distinct mouse hsp70 family members mot-1 and mot-2 proteins are encoded by two alleles. *DNA Res.* 7, 229-231.
- Kaul S., Reddel R.R., Sugihara T., Mitsui Y. and Wadhwa, R. (2000b). Inactivation of p53 and life span extension of human diploid fibroblasts by mot-2. *FEBS Lett.* 474, 159-164.
- Kaul S.C., Reddel R.R., Mitsui Y. and Wadhwa R. (2001). An N-terminal region of mot-2 binds to p53 *in vitro*. *Neoplasia* 3, 110-114.
- Krimmer T., Rassow J., Kunau W.H., Voos W. and Pfanner N. (2000). Mitochondrial protein import motor: the ATPase domain of matrix hsp70 is crucial for binding to Tim44, while the peptide binding domain and the carboxy-terminal segment play a stimulatory role. *Mol. Cell. Biol.* 20, 5879-5887.
- Marchenko N.D., Zaika A. and Moll U.M. (2000). Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. *J. Biol. Chem.* 275, 16202-16212.
- Merrick B.A., He C., Witcher L.L., Patterson R.M., Reid J.J., Pence-Pawlowski P.M. and Selkirk J.K. (1996). HSP binding and mitochondrial localization of p53 protein in human HT1080 and mouse C3H10T1/2 cell lines. *Biochim. Biophys. Acta* 13, 57-68.
- Merrick B.A., Walker V.R., He C., Patterson R.M. and Selkirk J.K. (1997). Induction of novel Grp75 isoforms by 2-deoxyglucose in human and murine fibroblasts. *Cancer Lett.* 119, 185-190.
- Michishita E., Nakabayashi K., Suzuki T., Kaul S.C., Ogino H., Fujii M., Mitsui Y. and Ayusawa D. (1999). 5-Bromodeoxyuridine induces senescence-like phenomena in mammalian cells regardless of cell type or species. *J. Biochem.* 126, 1052-1059.
- Mizukoshi E., Suzuki M., Loupatov A., Uruno T., Hayashi H., Misono T., Kaul S.C., Wadhwa R. and Imamura T. (1999). Fibroblast growth factor-1 interacts with the glucose-regulated protein GRP75/mortalin. *Biochem. J.* 343, 461-466.
- Mizukoshi E., Suzuki M., Misono T., Loupatov A., Munekata E., Kaul S.C., Wadhwa R. and Imamura T. (2001). Cell-cycle dependent tyrosine phosphorylation on mortalin regulates its interaction with fibroblast growth factor-1. *Biochem. Biophys. Res. Commun.* 280, 1203-1209.
- Moll U.M. and Schramm L.M. (1998). p53-an acrobat in tumorigenesis. *Crit. Rev. Oral Biol. Med.* 9, 23-37.
- Moll U.M., Riou G. and Levine A.J. (1992) Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. *Proc. Natl. Acad. Sci. USA* 89, 7262-7266.
- Moll U.M., Ostermeyer A.G., Haladay R., Winkfield B., Frazier M. and Zambetti G. (1996). Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. *Mol. Cell. Biol.* 16, 1126-1137.
- Nakabayashi K., Ogino H., Michishita E., Satoh N. and Ayusawa D. (1999). Introduction of chromosome 7 suppresses telomerase with shortening of telomeres in a human mesothelial cell line. *Exp. Cell*

Mortalin in biotechnology and biomedicine

- Res. 252, 376-382.
- Ohashi M., Oyanagi M., Hatakeyama K., Inoue M. and Kominami R. (1995). The gene encoding PBP74/CSA/mortalin-1, a novel mouse hsp70, maps to mouse chromosome 18. *Genomics* 30, 406-407.
- Ornatsky O.I., Connor M.K. and Hood D.A. (1995). Expression of stress proteins and mitochondrial chaperonins in chronically stimulated skeletal muscle. *Biochem. J.* 311, 119-123.
- Ran Q., Wadhwa R., Kawaki R., Kaul S.C., Sifers R.N., Bick R.J., Smith J.R. and Pereira-Smith O.M. (2000). Extra-mitochondrial localization of mortalin/mthsp70/PBP 74/GRP75. *Biochem. Biophys. Res. Commun.* 275, 174-179.
- Resendez E. Jr., Attenello J.W., Grafsky A., Chang C.S. and Lee A.S. (1985). Calcium ionophore A23187 induces expression of glucose-regulated genes and their heterologous fusion genes. *Mol. Cell. Biol.* 5, 1212-1219.
- Sacht G., Brigelius-Flohe R., Kiess M., Sztajer H. and Flohe L. (1999). ATP-sensitive association of mortalin with the IL-1 receptor type I. *Biofactors* 9, 49-60.
- Sadekova S., Lehnert S. and Chow T.Y. (1997). Induction of PBP74/mortalin/Grp75, a member of the hsp70 family, by low doses of ionizing radiation: a possible role in induced radioresistance. *Int. J. Radiat. Biol.* 72, 653-660.
- Schneider J.J. and Hood D.A. (2000). Effect of thyroid hormone on mtHsp70 expression, mitochondrial import and processing in cardiac muscle. *J. Endocrinol.* 165, 9-17.
- Singh B., Soltys B.J., Wu Z.C., Patel H.V., Freeman K.B. and Gupta R.S. (1997). Cloning and some novel characteristics of mitochondrial Hsp70 from Chinese hamster cells. *Exp. Cell Res.* 234, 205-216.
- Soltys B.J. and Gupta R.S. (1999). Mitochondrial-matrix proteins at unexpected locations: are they exported? *Trends Biochem. Sci.* 24, 174-177.
- Takahashi K. and Suzuki K. (1994). DNA synthesis-associated nuclear exclusion of p53 in normal human breast epithelial cells in culture. *Oncogene* 9, 183-188.
- Takahashi S., Mikami T., Watanabe Y., Okazaki M., Okazaki Y., Okazaki A., Sato T., Asaishi K., Hirata K., Narimatsu E. (1994). Correlation of heat shock protein 70 expression with estrogen receptor levels in invasive human breast cancer. *Am. J. Clin. Pathol.* 101, 519-525.
- Takahashi M., Chesley A., Freyssenet D. and Hood D.A. (1998). Contractile activity-induced adaptations in the mitochondrial protein import system. *Am. J. Physiol.* 274, C1380-C1387.
- Takano S., Wadhwa R., Yoshii Y., Nose T., Kaul S.C. and Mitsui Y. (1997). Elevated levels of mortalin expression in human brain tumors. *Exp. Cell Res.* 237, 38-45.
- Takano S., Wadhwa R., Mitsui Y. and Kaul S.C. (2001). Identification and characterization of molecular interactions between glucose-regulated proteins (GRPs) mortalin/GRP75/peptide-binding protein 74 (PBP74) and GRP94. *Biochem. J.* 357, 393-398.
- Wadhwa R., Kaul S.C., Ikawa Y. and Sugimoto Y. (1993a). Identification of a novel member of mouse hsp70 family. Its association with cellular mortal phenotype. *J. Biol. Chem.* 268, 6615-6621.
- Wadhwa R., Kaul S.C., Mitsui Y. and Sugimoto Y. (1993b). Differential subcellular distribution of mortalin in mortal and immortal mouse and human fibroblasts. *Exp. Cell Res.* 207, 442-448.
- Wadhwa R., Kaul S.C., Sugimoto Y. and Mitsui Y. (1993c). Induction of cellular senescence by transfection of cytosolic mortalin cDNA in NIH 3T3 cells. *J. Biol. Chem.* 268, 22239-22242.
- Wadhwa R., Pereira-Smith O.M., Reddel R.R., Sugimoto Y., Mitsui Y. and Kaul S.C. (1995). Correlation between complementation group for immortality and the cellular distribution of mortalin. *Exp. Cell Res.* 216, 101-106.
- Wadhwa R., Takano S., Robert M., Yoshida A., Reddel R.R., Nomura H., Mitsui Y. and Kaul S.C. (1998). Inactivation of tumor suppressor p53 by mot-2, an hsp70 family member. *J. Biol. Chem.* 273, 29586-29591.
- Wadhwa R., Takano S., Mitsui Y. and Kaul S.C. (1999). NIH 3T3 cells malignantly transformed by mot-2 show inactivation and cytoplasmic sequestration of the p53 protein. *Cell Res.* 9, 261-269.
- Wadhwa R., Sugihara T., Yoshida A., Nomura H., Reddel R.R., Simpson R., Maruta H. and Kaul S.C. (2000). Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function. *Cancer Res.* 60, 6818-6821.
- Wadhwa R., Yaguchi T., Hasan M.K., Mitsui Y., Reddel R.R. and Kaul S.C. (2002). Hsp70 family member, mot-2/mthsp70/GRP75, binds to the cytoplasmic sequestration domain of the p53 protein. *Exp. Cell Res.* 274, 246-253.
- Webster T.J., Naylor D.J., Hartman D.J., Hoj P.B. and Hoogenraad N.J. (1994). cDNA cloning and efficient mitochondrial import of pre-mtHSP70 from rat liver. *DNA Cell Biol.* 13, 1213-1220.
- Wu R., Zhao Y.H., Plopper C.G., Chang M.M., Chmiel K., Cross J.J., Weir A., Last J.A. and Tarkington B. (1999). Differential expression of stress proteins in nonhuman primate lung and conducting airway after ozone exposure. *Am. J. Physiol.* 277, L511-L522.
- Xu J., Xiao H.H. and Sartorelli A.C. (1999). Attenuation of the induced differentiation of HL-60 leukemia cells by mitochondrial chaperone HSP70. *Oncol. Res.* 11, 429-435.

Accepted May 20, 2002